[Clinical significance of bcl-2 protein expression and classification algorithm in diffuse large B-cell lymphoma]

Area of Science:

• Hematology
• Oncology
• Molecular Pathology

Context:

• Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma with variable clinical outcomes.
• Accurate prognostic markers are crucial for guiding treatment strategies and improving patient survival.
• Existing classification algorithms for DLBCL, such as Hans, Chan, and Muris models, aim to stratify patients based on biological subtypes.

Purpose:

• To evaluate the clinical significance of bcl-2 protein expression in DLBCL.
• To compare the efficacy of three classification algorithms (Hans, Chan, and Muris models) in predicting DLBCL prognosis.
• To determine the optimal combination of markers and algorithms for predicting patient outcomes.

Summary:

• Immunohistochemical analysis of 237 DLBCL cases revealed that bcl-2 protein expression is associated with an adverse prognosis (P = 0.019).
• The Chan's algorithm effectively distinguished between GCB and non-GCB subtypes, with the GCB subtype showing a significantly better prognosis (P = 0.031).
• Combining bcl-2 protein expression with the Chan's algorithm demonstrated the strongest predictive power for DLBCL patient outcomes, particularly in the non-GCB subgroup.

Impact:

• Identifies bcl-2 protein expression as a significant adverse prognostic factor in DLBCL.
• Highlights the superiority of the Chan's algorithm over Hans and Muris models in classifying DLBCL subtypes with prognostic relevance.
• Establishes bcl-2 expression combined with the Chan's algorithm as a potentially superior tool for predicting DLBCL patient outcomes, aiding in personalized treatment approaches.